Piramal Enterprises Ltd

Founded in 2003, Biodel is a pharmaceutical company that develops novel formulations for therapeutic care solutions. It offers medicines for the treatment of various endocrine disorders, including diabetes and osteoporosis. The company uses VIAdel technology, which enables delivery of endocrine therapeutics into blood through various routes of administration. Biodel also offers VIAject, which is an injectable human insulin product. It provides VIAtab, which is an oral human insulin product. The company offers VIAmass and VIAcal that formulates parathyroid hormone and salmon calcitonin for the treatment of osteoporosis. Additionally, Biodel provides a variety of clinical trial services and organizes various community events.

AVEO Oncology is a Boston-based biopharmaceutical company dedicated to improving the lives of cancer patients through innovative medical solutions. As a subsidiary of LG Chem, the company focuses on developing and delivering effective treatments that address the unique challenges faced by individuals battling cancer. Committed to scientific advancement, AVEO's portfolio includes several promising therapies, such as FOTIVDA, Ficlatuzumab, and AV-380. The company's mission is driven by a passion for enhancing the quality of life for those affected by cancer, underscoring their focus on patient-centered care. Generated from the website

Vigeo Therapeutics Inc is a clinical-stage biopharmaceutical company based in Boston, MA, dedicated to developing innovative therapeutics for various types of cancer. Their approach involves reprogramming the tumor immune microenvironment (TIME) to enhance cancer treatment outcomes. By activating thrombospondin-1 (Tsp-1), a natural anti-tumorigenic protein, Vigeo aims to target cancer cells and inhibit metastasis through CD36 and CD47 pathways. Vigeo Therapeutics is currently conducting clinical trials for VT1021, a peptide therapeutic agent, in patients with pancreatic, ovarian, triple negative breast cancers, glioblastoma, and tumors with high levels of CD36. Their commitment to advancing cancer treatment is evident through their recent clinical updates and presentations, showcasing their progress in the field of oncology.Generated from the website